News ReleaseView printer-friendly version
Quidel to Present at Wells Fargo Securities' Class of 2002 Conference
Mr. Kay is scheduled to speak on September 4, 2002, at approximately 2:00 p.m. Eastern Time (11:00 am Pacific Time). Interested investors can access the live audio webcast of the presentation by going to Quidel's Web site at http://www.quidel.com . A replay of the audio webcast will be available for seven days starting September 6, 2002, on Quidel's Web site.
Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point- of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com .
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
media, Bea Evangelista of Euro RSCG Middleberg,
+1-212-699-2503, firstname.lastname@example.org, for Quidel Corporation; or
investors, Ina McGuinness of Lippert/Heilshorn & Assoc., +1-310-691-7100,
email@example.com, for Quidel Corporation; or Paul E. Landers, Vice
President & Chief Financial Officer of Quidel Corporation, +1-858-552-7962